“Innovation in Human Milk Oligosaccharide (HMO) Integration”
- A prominent trend in the Asia-Pacific prebiotics for infant formula market is the increasing inclusion of Human Milk Oligosaccharides (HMOs), which closely mimic the beneficial prebiotics found in natural breast milk. HMOs support gut health, immunity, and cognitive development in infants, making them a key focus area for premium formula brands
- For instance, Abbott Laboratories has introduced formulas containing 2’-FL HMO under its Similac brand in Asia-Pacific markets, aimed at replicating the natural benefits of breast milk for non-breastfed infants
- Market players are investing in biotechnology-driven fermentation processes to produce HMOs at scale. Companies such as DSM and FrieslandCampina Ingredients are collaborating with local brands to expand HMO-based offerings in countries such as China, Japan, and India
- The surge in research linking HMOs to stronger immune responses and long-term infant health is driving increased parental preference for formulas that offer similar nutritional advantages to breastfeeding
- As scientific advancements continue, the integration of multiple HMOs and customization of prebiotic blends are expected to become a central differentiator in product innovation, further shaping consumer demand in the region
